Affiliation:
1. Mayo Clinic, Phoenix, AZ 85054, USA
2. Phoenix Country Day School, Paradise Valley, AZ 85253, USA
Abstract
Endocrine therapy is the main treatment for hormone receptor-positive (HR+) breast cancer. However, advanced tumors develop resistance to endocrine therapy, rendering it ineffective as the disease progresses. There are several molecular mechanisms of primary and secondary endocrine resistance. Resistance can develop due to either alteration of the estrogen receptor pathway (e.g., ESR1 mutations) or upstream growth factors signaling pathways (e.g., PI3K/Akt/mTOR pathway). Despite progress in the development of molecularly targeted anticancer therapies, the emergence of resistance remains a major limitation and an area of unmet need. In this article, we review the mechanisms of acquired endocrine resistance in HR+ advanced breast cancer and discuss current and future investigational therapeutic approaches.
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference113 articles.
1. Cancer statistics, 2023;Siegel;CA Cancer J. Clin.,2023
2. Clusan, L., Ferrière, F., Flouriot, G., and Pakdel, F. (2023). A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer. Int. J. Mol. Sci., 24.
3. Mechanisms of endocrine resistance in breast cancer;Osborne;Annu. Rev. Med.,2011
4. Endocrine-resistant breast cancer: Mechanisms and treatment;Hartkopf;Breast Care,2020
5. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2);Cardoso;Breast,2014
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献